hydroxychloroquine has been researched along with paclitaxel in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bythell, B; Clark, S; Collis, C; Lasseter, L; Ledwitch, K; Manning, TJ; Ogburn, R; Patterson, S; Phillips, D; Wylie, G | 1 |
| Krajewski, L; Manning, T; Phillips, D; Plummer, S; Woods, R; Wylie, G | 1 |
| Duan, Z; Gao, P; Garbutt, C; Hornicek, FJ; Kan, Q; Ma, H; Shi, H; Wang, J | 1 |
| He, Q; Li, M; Liu, J; Rao, J; Tang, X; Wan, D; Wang, X; Wang, Y; Wei, J; Xia, C; Yin, S; Zhang, Z | 1 |
| Amaravadi, RK; Borazanci, E; Burrell, JA; De Jesus-Acosta, A; Drebin, JA; Karasic, TB; Laheru, DA; Loaiza-Bonilla, A; O'Dwyer, PJ; O'Hara, MH; Redlinger, C; Reiss, KA; Teitelbaum, UR; Von Hoff, DD | 1 |
| Chen, X; He, Q; Li, M; Liu, Y; Sheng, Q; Shi, K; Wang, Y; Yu, Q; Zhang, Z | 1 |
| Amaravadi, RK; Bahary, N; Bartlett, DL; Boone, BA; Espina, V; Hogg, ME; Lee, KK; Liotta, L; Lotze, MT; Marsh, JW; Miller-Ocuin, JL; Murthy, P; Normolle, DP; Seiser, N; Singhi, AD; Tang, D; Tsung, A; Zeh, HJ; Zureikat, AH | 1 |
| He, J; He, Q; Li, J; Li, M; Long, Y; Qiu, Y; Ren, K; Wang, X; Xu, Z; Yang, Y; Zang, S; Zhang, Z | 1 |
1 review(s) available for hydroxychloroquine and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for hydroxychloroquine and paclitaxel
| Article | Year |
|---|---|
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Hydroxychloroquine; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2019 |
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxychloroquine; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Preoperative Care; Recurrence; Survival Analysis; Treatment Outcome | 2020 |
7 other study(ies) available for hydroxychloroquine and paclitaxel
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Copper ion as a delivery platform for taxanes and taxane complexes.
Topics: Antimalarials; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Copper; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Hydroxychloroquine; Ions; Molecular Structure; Organometallic Compounds; Paclitaxel; Structure-Activity Relationship; Taxoids | 2014 |
Cell line studies and analytical measurements of three paclitaxel complex variations.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Copper; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydroxychloroquine; Models, Molecular; Molecular Structure; Organometallic Compounds; Paclitaxel; Structure-Activity Relationship; Sucrose | 2017 |
Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Humans; Hydroxychloroquine; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Sequestosome-1 Protein | 2018 |
Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line; Humans; Hydroxychloroquine; Integrin alphaVbeta3; Liposomes; Lung Neoplasms; Melanoma; Mice, Inbred C57BL; Neuropilin-1; Oligopeptides; Paclitaxel; Paxillin; Phosphatidylethanolamines; Polyethylene Glycols; Receptors, CXCR4 | 2018 |
Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Topics: Animals; Antineoplastic Agents; Autophagy; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Disease Progression; Female; Fibrosis; Humans; Hydroxychloroquine; Irinotecan; Liposomes; Mice; Mice, Nude; Nanomedicine; Neoplasm Metastasis; Neoplasm Transplantation; NIH 3T3 Cells; Paclitaxel; Pancreatic Neoplasms; Peptides; Wound Healing | 2019 |
A neutrophil-mediated carrier regulates tumor stemness by inhibiting autophagy to prevent postoperative triple-negative breast cancer recurrence and metastasis.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydroxychloroquine; Inflammation; Liposomes; Neoplasm, Residual; Neutrophils; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |